PT-141 dosage protocol explained: FDA-approved Vyleesi dosing, research peptide ranges, timing, side effects, and what to discuss with your doctor.
The PT-141 dosage protocol with the strongest human evidence is the FDA-approved one: bremelanotide, sold as Vyleesi, given as a single 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity, never more than once in 24 hours and no more than eight times per month. That approval covers premenopausal women with hypoactive sexual desire disorder (HSDD) only. PT-141 bought from research peptide sellers is a different product with no approved human dose, no guaranteed purity, and no safety monitoring.
What the FDA-Approved PT-141 Dosage Protocol Is
Vyleesi is supplied as a single-use autoinjector that delivers 1.75 mg of bremelanotide in 0.3 mL. It is injected under the skin of the abdomen or thigh. There is no titration phase, because the starting dose is also the maintenance dose.
- Dose: 1.75 mg, one autoinjector, fixed.
- Timing: at least 45 minutes before sexual activity.
- Frequency: maximum one dose per 24 hours and eight doses per 30 days.
- Site: subcutaneous, abdomen or thigh, rotating the injection site.
Bremelanotide is not a daily medication that builds up in the body. It acts on melanocortin receptors in the brain and is used on demand. The label notes that it can cause a temporary rise in blood pressure and a drop in heart rate, which is why a clinician may check your blood pressure before prescribing.
Bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease, and it should not be combined with naltrexone-containing medications.
PT-141 Dosage for Men vs Women
The approved PT-141 population is premenopausal women. Postmenopausal women and men were not included in the trials that supported approval, and the manufacturer does not market the drug for them.
Older studies of bremelanotide in men with erectile dysfunction showed only modest improvements, and the FDA did not approve it for male use. When people search for a pt 141 dosage for men, they usually land on informal reports of 1 to 2 mg injected subcutaneously, numbers borrowed from research settings rather than from any label.
A 10 mg research vial is easy to misread as a 10 mg dose, but 10 mg is the total powder in the vial before reconstitution, not the amount used at one time. Reconstituting a 10 mg vial with 1 mL of bacteriostatic water produces 10 mg/mL, so a 1.75 mg amount would be about 0.18 mL.
Anyone considering PT-141 should talk with a healthcare professional about whether an approved option fits their situation before using an unregulated product.
How Research Peptide Protocols Compare to the Label
Most online content about peptide pt-141 dosage comes from research chemical vendors and user forums. These sources describe a wide range of doses, routes, and schedules, and none of them provide medical oversight.
| Factor | FDA-approved Vyleesi | Research peptide use |
|---|---|---|
| Dose | 1.75 mg, fixed | Roughly 0.5 to 2 mg reported |
| Route | Subcutaneous autoinjector | Subcutaneous syringe after reconstitution |
| Frequency | Maximum 1 dose per 24 hours, 8 per month | Variable and often undefined |
| Purity testing | FDA-inspected manufacturing | Certificates of analysis vary and are often absent |
| Human safety data | Yes, from controlled trials | None |
| Legal status | Prescription drug | Sold for research use only, not for human use |
A pt-141 peptide dosage chart from a vendor is not equivalent to clinical guidance. Research peptides are commonly sold as lyophilized powder, and the certificate of analysis may or may not match the actual contents. Sterility, correct peptide identity, and accurate concentration are not guaranteed.
One more caution comes straight from the clinical data: higher doses in early trials produced more nausea without clearly better results. More is not better with bremelanotide.
Subcutaneous Injection and Other Routes
Subcutaneous injection is the only route with an approved product. Questions about pt-141 dosage subcutaneous are answered by the label: one 1.75 mg injection into the abdomen or thigh, given 45 minutes ahead of activity.
Bremelanotide was originally studied as an intranasal spray. Nasal absorption was inconsistent and nausea rates were high, and the approved product is not a nasal formulation. Any pt 141 nasal spray dosage circulating online is based on older research or anecdotal reports, not on an approved product.
- Subcutaneous: approved, predictable absorption, roughly 45-minute onset.
- Intranasal: not approved, variable absorption, historically more nausea and blood pressure effects.
- Oral: not viable, because bremelanotide is poorly absorbed and broken down in the gut.
Timing, Side Effects, and Safety
Nausea is the most commonly reported side effect of bremelanotide and affected roughly 40% of participants in clinical trials. Flushing, headache, injection-site reactions, and vomiting are also common, and these effects tend to be strongest in the first few hours after dosing.
Repeated use has been linked to focal hyperpigmentation, which means darker patches of skin, including on the face and gums. This is more likely with frequent dosing, which is one reason the label caps use at eight doses per month.
Bremelanotide may cause fetal harm and is not recommended during pregnancy, so pregnancy should be ruled out before starting it. It is not a contraceptive and does not protect against sexually transmitted infections.
Because bremelanotide raises blood pressure temporarily, people with uncontrolled hypertension or established cardiovascular disease should not use it. Combining it with naltrexone-containing products is contraindicated. Tell your clinician about any blood pressure medication, antidepressant, or other prescription you take.
Frequently Asked Questions
What is the correct PT-141 dosage?
For the FDA-approved product, Vyleesi, the dose is 1.75 mg injected subcutaneously at least 45 minutes before sexual activity. The maximum is one dose in 24 hours and eight doses per month. That dose is approved only for premenopausal women with hypoactive sexual desire disorder; there is no approved dose for men or for research-grade PT-141.
How long does PT-141 take to work?
Bremelanotide is typically taken about 45 minutes before anticipated sexual activity, which is when effects begin to be noticed. Side effects such as nausea and flushing also tend to appear in that early window and usually ease over the following hours. Taking it later than 45 minutes ahead may mean the dose peaks after the moment you wanted it for.
Can men use PT-141?
Bremelanotide is not FDA-approved for men. Trials in men with erectile dysfunction showed only modest benefit, and the FDA approved the drug for premenopausal women with HSDD instead. Any male dosing information found online comes from research settings or anecdotal reports, not from an approved label, so a clinician should be involved in any decision.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.